Eli Lilly's Foundayo Cuts Sleep Apnea Severity By Up To 44% In Phase 3 Trials
(RTTNews) - Eli Lilly and Company (LLY) on Monday announced positive Phase 3 results showing that its oral obesity drug Foundayo (orforglipron) significantly reduced obstructive sleep apnea (OSA) severity in adults with obesity or overweight.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Eli Lilly releases Foundayo sleep apnea data seekingalpha.com
